VTR
70
7
ZION
55
3
AVB
69
4
EQR
67
5
AMT
62
4
ADBE
51
2
NVDA
59
3
AIG
56
2
CINF
51
-2
HOG
33
6
SWK
64
-13
VMC
74
2
KMB
48
-2
PCG
93
4
C
46
2
PLD
51
13
A
44
-2
EMN
72
3
CFG
44
18
WRK
73
8
VTR
70
7
ZION
55
3
AVB
69
4
EQR
67
5
AMT
62
4
ADBE
51
2
NVDA
59
3
AIG
56
2
CINF
51
-2
HOG
33
6
SWK
64
-13
VMC
74
2
KMB
48
-2
PCG
93
4
C
46
2
PLD
51
13
A
44
-2
EMN
72
3
CFG
44
18
WRK
73
8
Financhill
Back

Pacira BioSciences 10K Form

Sell
47

PCRX
Pacira BioSciences

Last Price:
27.33
Seasonality Move:
2.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $674.98M
Cash Flow: $45.79M
Price / Cash Flow: 10.72
Annual Sales: $18.72
Price / Book: 1.46

Profitability

EPS (TTM): 0.83000
Net Income (TTM): $41.96M
Gross Margin: $490.31M
Return on Equity: 5.18%
Return on Assets: 2.67%

Pacira BioSciences Earnings Forecast

Key Pacira BioSciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for PCRX is 72.64%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 39.92% of Gross Profit Margin.
  • The Research & Development expenses have been 11.30% of Revenue.
  • The Interest Expense is 41.26% of Operating Income.
  • The Net Earning history of PCRX is 6.22% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 8 years.

Pacira BioSciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.6
Current Ratio: 5.24
Quick Ratio: 3.94

Price-to-Earnings

Trailing P/E Ratio: 30.7
Forward P/E Ratio: 7.67

PCRX Technical Analysis vs Fundamental Analysis

Sell
47
Pacira BioSciences (PCRX) is a Sell

Is Pacira BioSciences a Buy or a Sell?